Page 2
-
Q&A
Neuroscience has entered a new era. Now it’s time for a ‘moonshot’ approach.
Dr. Jeremy Levin, CEO of Ovid Therapeutics, explains how scientific advances have converged to create a new era of drug development potential.
-
As Lilly and BMS invest in manufacturing, demand for drugs still outweighs supply
From popular weight loss drugs to lifesaving cancer therapies, recent pharma deals show the industry is doubling down on manufacturing capacity to meet demand.
-
Biogen: Don’t expect any big acquisitions this year
While the company is eager to diversify, CEO Chris Viehbacher said that in the near-term any dealmaking would likely focus on collaborations and early-stage assets.
-
Q&A
AbbVie and Regenxbio’s ‘multibillion-dollar opportunity’ in vision loss gene therapy
After a successful mid-stage study, the companies aim to upend traditional wet AMD treatments with a one-time gene therapy.
-
Inside J&J’s strategy to de-gender clinical trials
Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.
-
Vistagen’s on-demand nasal spray could provide a novel option for social anxiety
The fast-acting medication is one of a few new approaches being tested for the crippling condition.
-
WuXi partnerships at risk as lawmakers target Chinese ties to biopharma
Why the legislation could throw a wrench into the supply chain for advanced therapies and how the industry has responded.
-
Deep Dive
Ukraine was pharma’s ‘darling’ of clinical trials. As war drags on, will the industry come back?
New clinical trial starts are picking back up, but are still far below their bustling pre-war level.
-
Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug
Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.
-
Roivant spinoff tackles growing complexity of clinical trials
As precision medicine booms, all trials are starting to look like rare disease trials, the company said.
-
3 patent expirations in 2024 and how companies are pivoting
As the cliffs approach, pharma companies are tackling the sales hit with diverging strategies.
-
Where the GLP-1 weight loss market goes will depend on data
As GLP-1s expand into new disease categories, their impact could be enough to overtake leading cardiovascular drugs.
-
3 big recent trial flops
How these clinical setbacks impacted the companies, industry and patients.
-
Biotech Spotlight
Traditional gene therapies are uber-niche. Ocugen hopes to change that.
The biotech is developing a ‘gene-agnostic’ approach to expand the patient pool for gene therapies.
-
Deep Dive
Psychiatry drugs finally have pharma’s attention. Can they keep it?
Recent biotech company acquisitions have put emerging schizophrenia treatments in focus. But many development hurdles still stand in the way of new medicines for the brain.
-
Biosimilar uptake appears to finally be on the upswing, and Biocon Biologics is betting on the sector’s future
Biosimilars promise market competition for branded biologics, which in theory could drive down prices. But so far, winning market share has been a struggle.
-
Cutting pills. Rationing insulin. How Americans struggle to pay for drugs.
More than 20% of Americans are forgoing prescription medications due to costs, according to a recent survey.
-
Women want to participate in clinical trials. Lack of flexibility is still a problem.
Underrepresentation of women in clinical trials affects the resulting drugs that are available down the line, but even small changes can fuel participation.
-
Next-gen menopause treatments have blockbuster potential. Can women, doctors and payers be convinced?
The market is huge, but will companies overcome the triple hurdles of payer hesitance, prescriber reluctance and sluggish consumer demand?
-
Q&A // First 90 Days
With an ovarian KRAS combo ready for review, Verastem’s CEO is poised for the transition
As its FDA filing approaches, Verastem Oncology CEO Daniel Paterson wants to go from “The Little Engine That Could” to a major oncology player.
-
Viral return: 3 U.S. cases concerning experts
Infectious diseases that were “off the playing field” are now making a comeback.
-
As antimicrobial resistance looms large, a nonprofit teams up with Big Pharma to intervene
AMR is a growing threat, but with little financial incentive to pick up the torch, government and nonprofit collaborations are keeping the R&D flames burning.
-
A dementia-focused VC digs past anti-amyloid for neuroscience diamonds in the rough
Even as new drugs like Eisai and Biogen’s Leqembi make a splash in Alzheimer’s, VCs like the Dementia Discovery Fund have invested in the next wave of therapies.
-
With a rise in animal-human organ transplants, a drugmaker aims for a new standard of care
Eledon Pharmaceuticals is developing a drug that could facilitate organ transplants from animals to humans as the procedure gains steam.
-
Q&A
To advance women’s leadership, an effort ‘has to be purposeful,’ says EMD Serono exec
Gender diversity in leadership “doesn’t just happen,” — it requires institutional change, from investing in women’s startups to providing more generous family leave.